MedPage Today on MSN

First drug for deadly transplant complication gets FDA's blessing

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
Business Wire

International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury

Omeros also has identified MASP-3 as the protein that is critical to the activation of the complement system’s alternative pathway in humans, which is linked to a wide range of immune-related ...
Business Wire

FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...